We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Actinium Pharmaceuticals (ATNM) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Actinium Pharmaceuticals (ATNM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Actinium Pharmaceuticals is a member of our Medical group, which includes 817 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 10.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATNM has moved about 7.63% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.96% on average. This shows that Actinium Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 1.07% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Actinium Pharmaceuticals (ATNM) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Actinium Pharmaceuticals (ATNM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Actinium Pharmaceuticals is a member of our Medical group, which includes 817 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 10.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATNM has moved about 7.63% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.96% on average. This shows that Actinium Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 1.07% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.